H.C. Wainwright keeps a Neutral rating on Alkermes (ALKS) with a $46 price target following the Q4 report. The company’s Q4 was bolstered by tailwinds, but the outlook is reassuring and reflects underlying strength, the analyst tells investors in a research note. The firm says expanding the next-generation orexins to additional indications is gaining momentum at Alkermes. H.C. Wainwright assigns a 50% probability of success for ALKS 2680 as a Phase 2 asset.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALKS:
- Alkermes price target raised to $38 from $35 at TD Cowen
- Alkermes price target raised to $34 from $33 at BofA
- Alkermes: Stability with Limited Upside Amid Program Expectations and Competitive Pressures
- Alkermes plc Reports Strong 2024 Financial Results
- Alkermes’ Strong Financial Performance and Future Growth Prospects Drive Buy Rating